AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES by and between POZEN INC. and ASTRAZENECA AB November 18, 2013Collaboration and License Agreement • May 23rd, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
LICENSE AGREEMENT By and between AstraZeneca AB and Horizon Pharma USA, Inc. Dated as of November 22, 2013License Agreement • May 23rd, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into effective as of November 22, 2013 (the “Effective Date”) by and between AstraZeneca AB, a Swedish corporation (“AstraZeneca”), and Horizon Pharma USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Horizon”). AstraZeneca and Horizon are sometimes referred herein individually as a “Party” and collectively as the “Parties.”
SUPPLY AGREEMENTSupply Agreement • May 23rd, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS SUPPLY AGREEMENT (“Agreement”) is made and entered into effective as of November 22, 2013 (the “Effective Date”), by and between ASTRAZENECA LP, a Delaware limited partnership (“AstraZeneca”), having offices at 1800 Concord Pike, Wilmington, Delaware 19803, and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon”), having an office at 520 Lake Cook Road, Suite 520, Deerfield, Illinois 60015. AstraZeneca and Horizon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
ASSET PURCHASE AGREEMENT By and between AstraZeneca AB and Horizon Pharma USA, Inc. Dated as of November 18, 2013Asset Purchase Agreement • May 23rd, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made and executed as of November 18, 2013 (the “Execution Date”), by and between AstraZeneca AB, a Swedish corporation (“AstraZeneca”), and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon”). AstraZeneca and Horizon are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Master Manufacturing Services Agreement October 31, 2013Product Agreement • May 23rd, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
